[go: up one dir, main page]

AR133725A1 - POLYPEPTIDES FOR USE IN THE TREATMENT OF GLYPICAN-3 EXPRESSING TUMORS - Google Patents

POLYPEPTIDES FOR USE IN THE TREATMENT OF GLYPICAN-3 EXPRESSING TUMORS

Info

Publication number
AR133725A1
AR133725A1 ARP240102353A ARP240102353A AR133725A1 AR 133725 A1 AR133725 A1 AR 133725A1 AR P240102353 A ARP240102353 A AR P240102353A AR P240102353 A ARP240102353 A AR P240102353A AR 133725 A1 AR133725 A1 AR 133725A1
Authority
AR
Argentina
Prior art keywords
treatment
polypeptides
glypican
expressing tumors
relates
Prior art date
Application number
ARP240102353A
Other languages
Spanish (es)
Inventor
Giovanni Abbadessa
Serena Masciara
Wan-Ju Meng
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR133725A1 publication Critical patent/AR133725A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente tecnología se refiere al campo del tratamiento del cáncer. En particular, se refiere a polipéptidos dirigidos a Glipicano-3 (GPC3) y al receptor de linfocitos T (TCR) para su uso en el tratamiento de tumores sólidos positivos para glipicano-3 (GPC3+), tales como carcinoma hepatocelular (HCC) o cáncer de pulmón no microcítico (NSCLC). Además, se refiere a la dosificación de dicho polipéptido cuando se utiliza como tratamiento.This technology relates to the field of cancer treatment. In particular, it relates to polypeptides targeting Glipican-3 (GPC3) and the T-cell receptor (TCR) for use in the treatment of glipican-3-positive (GPC3+) solid tumors, such as hepatocellular carcinoma (HCC) or non-small cell lung cancer (NSCLC). It also relates to the dosage of such polypeptide when used as a treatment.

ARP240102353A 2023-09-04 2024-09-04 POLYPEPTIDES FOR USE IN THE TREATMENT OF GLYPICAN-3 EXPRESSING TUMORS AR133725A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23306466 2023-09-04
EP24305204 2024-02-06

Publications (1)

Publication Number Publication Date
AR133725A1 true AR133725A1 (en) 2025-10-29

Family

ID=92633941

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102353A AR133725A1 (en) 2023-09-04 2024-09-04 POLYPEPTIDES FOR USE IN THE TREATMENT OF GLYPICAN-3 EXPRESSING TUMORS

Country Status (3)

Country Link
AR (1) AR133725A1 (en)
TW (1) TW202525843A (en)
WO (1) WO2025051767A1 (en)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
KR100508289B1 (en) 1998-04-21 2005-08-17 마이크로메트 에이지 Cd19×cd3 specific polypeptides and uses thereof
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
EP1157119A1 (en) 1999-02-05 2001-11-28 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
DE60035163T2 (en) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver ABC1 POLYPEPTIDES AND METHOD AND REAGENTS FOR MODULATING THE CHOLESTEROL CONTENT
WO2000078972A2 (en) 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Regulation with binding cassette transporter protein abc1
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
DE19955408A1 (en) 1999-11-18 2001-05-23 Bayer Ag New invertebrate gamma-aminobutyric acid receptor proteins, useful in screening for potential insecticides, for plant protection or medicine, also related nucleic acid
AU2003284891A1 (en) 2002-10-23 2004-05-13 Ludwig Institute For Cancer Research A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN103254309B (en) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 For the improved nanometer body of tumor necrosis factor αTM
ES2856451T3 (en) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Compositions comprising specific antibodies for different species, and uses thereof
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
NZ780183A (en) 2011-06-23 2024-12-20 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
PT3248986T (en) 2014-05-16 2022-04-05 Ablynx Nv Immunoglobulin variable domains
EP3611192B1 (en) 2015-05-13 2025-03-05 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
EP3974449A1 (en) 2015-11-13 2022-03-30 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
CN120535622A (en) 2015-11-18 2025-08-26 埃博灵克斯股份有限公司 Improved serum albumin binders
CN117164710A (en) 2016-12-07 2023-12-05 埃博灵克斯股份有限公司 Improved serum albumin binding immunoglobulin single variable domains
ES2991459T3 (en) 2017-01-17 2024-12-03 Ablynx Nv Improved serum albumin binders
SG10202108973SA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
EP4126971A1 (en) 2020-03-30 2023-02-08 Ablynx N.V. Method for the production and purification of multivalent immunoglobulin single variable domains
WO2022129637A1 (en) * 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
IL303783A (en) 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising single immunoglobulin variable sites targeting GLYPICAN-3 and the T-cell receptor
US20240109965A1 (en) * 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor

Also Published As

Publication number Publication date
WO2025051767A1 (en) 2025-03-13
TW202525843A (en) 2025-07-01

Similar Documents

Publication Publication Date Title
Hua et al. miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA
Qin et al. Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway
Xu et al. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial–mesenchymal transition
Liu et al. The small molecule chemical compound cinobufotalin attenuates resistance to DDP by inducing ENKUR expression to suppress MYH9-mediated c-Myc deubiquitination in lung adenocarcinoma
Xie et al. Astragaloside IV enhances cisplatin chemosensitivity in human colorectal cancer via regulating NOTCH3
Zhu et al. MyD88 regulates LPS-induced NF-ĸB/MAPK cytokines and promotes inflammation and malignancy in colorectal cancer cells
Zhang et al. Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer
MX2021001158A (en) Oncolytic hsv vector.
Ma et al. Emodin inhibits LOVO colorectal cancer cell proliferation via the regulation of the Bcl-2/Bax ratio and cytochrome c
EP2582727A4 (en) ANTIBODIES AGAINST ENDOPLASMINE AND THEIR USE
Ma et al. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53-p66 shc pathway.
MX2021001938A (en) Immunotherapy targeting kras or her2 antigens.
Dander et al. Monocyte–macrophage polarization and recruitment pathways in the tumour microenvironment of B‐cell acute lymphoblastic leukaemia
Zheng et al. Oridonin promotes G2/M arrest in A549 cells by facilitating ATM activation
Zhang et al. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance
Lam et al. E2F1 downregulation by arsenic trioxide in lung adenocarcinoma
WO2014145817A3 (en) Novel therapeutic target for the treatment of cancers and related therapies and methods
Du et al. Polyphyllin VII promotes apoptosis in breast cancer by inhibiting MAPK/ERK signaling pathway through downregulation of SOS1
AR133725A1 (en) POLYPEPTIDES FOR USE IN THE TREATMENT OF GLYPICAN-3 EXPRESSING TUMORS
Liu et al. PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma
BR112021008973A8 (en) SPECIFIC T CELL RECEPTORS FOR MESOTHELIN AND THEIR USE IN IMMUNOTHERAPY
Lv et al. Sinomenine inhibits proliferation of SGC-7901 gastric adenocarcinoma cells via suppression of cyclooxygenase-2 expression
Xu et al. Polygonatum sibiricum component liquiritigenin restrains breast cancer cell invasion and migration by inhibiting HSP90 and chaperone-mediated autophagy
Fan et al. Bushenshugan formula attenuates the development of lung cancer by inhibiting epithelial-mesenchymal transition
Canale et al. CD39 as a marker of pathogenic CD8+ T cells in cancer and other chronic inflammatory diseases